What is the Return on Assets (ROA) of Dae Hwa Pharm Co this year?
The Return on Assets (ROA) of Dae Hwa Pharm Co is -0.01 undefined this year.
In 2024, Dae Hwa Pharm Co's return on assets (ROA) was -0.01, a -193.36% increase from the 0.01 ROA in the previous year.
Dae Hwa Pharm Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Comparing Dae Hwa Pharm Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Investors consider Dae Hwa Pharm Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Variations in Dae Hwa Pharm Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
The Return on Assets (ROA) of Dae Hwa Pharm Co is -0.01 undefined this year.
The ROA of Dae Hwa Pharm Co has increased by -193.36% compared to the previous year.
A high ROA is advantageous for investors of Dae Hwa Pharm Co, as it indicates that the company efficiently utilizes its assets and generates good profits.
A low ROA can be unfavorable for investors of Dae Hwa Pharm Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
An increase in ROA of Dae Hwa Pharm Co can be an indicator of improved efficiency in asset utilization and higher profitability.
A reduction in the ROA of Dae Hwa Pharm Co can be an indicator of lower asset efficiency and profitability.
Some factors that can influence the ROA of Dae Hwa Pharm Co include revenue, operating costs, asset structure, and industry average.
The ROA of Dae Hwa Pharm Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
To improve ROA, Dae Hwa Pharm Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
Over the past 12 months, Dae Hwa Pharm Co paid a dividend of 150 KRW . This corresponds to a dividend yield of about 1.28 %. For the coming 12 months, Dae Hwa Pharm Co is expected to pay a dividend of 150 KRW.
The current dividend yield of Dae Hwa Pharm Co is 1.28 %.
Dae Hwa Pharm Co pays a quarterly dividend. This is distributed in the months of January, July, January, July.
Dae Hwa Pharm Co paid dividends every year for the past 20 years.
For the upcoming 12 months, dividends amounting to 150 KRW are expected. This corresponds to a dividend yield of 1.28 %.
Dae Hwa Pharm Co is assigned to the 'Health' sector.
To receive the latest dividend of Dae Hwa Pharm Co from 8/23/2024 amounting to 50 KRW, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
The last dividend was paid out on 8/23/2024.
In the year 2023, Dae Hwa Pharm Co distributed 150 KRW as dividends.
The dividends of Dae Hwa Pharm Co are distributed in KRW.
Our stock analysis for Dae Hwa Pharm Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dae Hwa Pharm Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.